{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:31:33Z","timestamp":1671618693214},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00259-011-2040-5","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T13:13:45Z","timestamp":1326287625000},"page":"956-966","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan"],"prefix":"10.1007","volume":"39","author":[{"given":"C.","family":"Arrichiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Aloj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mormile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Frigeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Carac\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arcamone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Martinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"2040_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","volume":"3","author":"AV Rao","year":"2005","unstructured":"Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res. 2005;3:157\u201365.","journal-title":"Clin Med Res"},{"key":"2040_CR2","first-page":"1017","volume":"15","author":"PC Chinn","year":"1999","unstructured":"Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol. 1999;15:1017\u201325.","journal-title":"Int J Oncol"},{"key":"2040_CR3","first-page":"1507","volume":"43","author":"ME Juweid","year":"2002","unstructured":"Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507\u201329.","journal-title":"J Nucl Med"},{"key":"2040_CR4","first-page":"457","volume":"2","author":"SJ Knox","year":"1996","unstructured":"Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457\u201370.","journal-title":"Clin Cancer Res"},{"key":"2040_CR5","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156\u201364.","journal-title":"J Clin Oncol"},{"key":"2040_CR6","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"2040_CR7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804\u201310.","journal-title":"Cancer"},{"key":"2040_CR8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","volume":"2","author":"AJ Grillo-Lopez","year":"2002","unstructured":"Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther. 2002;2:485\u201393.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2040_CR9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beha.2011.03.005","volume":"24","author":"T Illidge","year":"2011","unstructured":"Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:279\u201393.","journal-title":"Best Pract Res Clin Haematol."},{"issue":"Suppl 2","key":"2040_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","volume":"14","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist. 2009;14 Suppl 2:17\u201329.","journal-title":"Oncologist"},{"key":"2040_CR11","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793\u2013803.","journal-title":"J Clin Oncol"},{"key":"2040_CR12","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","volume":"26","author":"L Devizzi","year":"2008","unstructured":"Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol. 2008;26:5175\u201382.","journal-title":"J Clin Oncol"},{"key":"2040_CR13","first-page":"215","volume":"1","author":"SA Jacobs","year":"2007","unstructured":"Jacobs SA. Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics. 2007;1:215\u201327.","journal-title":"Biologics"},{"key":"2040_CR14","first-page":"1812","volume":"46","author":"PS Conti","year":"2005","unstructured":"Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005;46:1812\u20138.","journal-title":"J Nucl Med"},{"key":"2040_CR15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","volume":"27","author":"GA Wiseman","year":"2000","unstructured":"Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766\u201377.","journal-title":"Eur J Nucl Med."},{"key":"2040_CR16","first-page":"465","volume":"44","author":"GA Wiseman","year":"2003","unstructured":"Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465\u201374.","journal-title":"J Nucl Med"},{"key":"2040_CR17","first-page":"1381","volume":"35","author":"S Shen","year":"1994","unstructured":"Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med. 1994;35:1381\u20139.","journal-title":"J Nucl Med"},{"key":"2040_CR18","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2967\/jnumed.107.044016","volume":"48","author":"M Cremonesi","year":"2007","unstructured":"Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, et al. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med. 2007;48:1871\u20139.","journal-title":"J Nucl Med"},{"key":"2040_CR19","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2967\/jnumed.110.079897","volume":"51","author":"D Minarik","year":"2010","unstructured":"Minarik D, Sjogreen-Gleisner K, Linden O, Wingardh K, Tennvall J, Strand SE, et al. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974\u20138.","journal-title":"J Nucl Med"},{"key":"2040_CR20","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336\u201342.","journal-title":"Blood"},{"key":"2040_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.semnuclmed.2003.11.001","volume":"34","author":"AM Zimmer","year":"2004","unstructured":"Zimmer AM. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34:14\u20139.","journal-title":"Semin Nucl Med"},{"key":"2040_CR22","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689\u201394.","journal-title":"J Nucl Med"},{"key":"2040_CR23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/108497802760363213","volume":"17","author":"MG Stabin","year":"2002","unstructured":"Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17:427\u201333.","journal-title":"Cancer Biother Radiopharm"},{"key":"2040_CR24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/cbr.2007.307","volume":"22","author":"M Holstensson","year":"2007","unstructured":"Holstensson M, Hindorf C, Ljungberg M, Partridge M, Flux GD. Optimization of energy-window settings for scatter correction in quantitative (111)In imaging: comparison of measurements and Monte Carlo simulations. Cancer Biother Radiopharm. 2007;22:136\u201342.","journal-title":"Cancer Biother Radiopharm"},{"key":"2040_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10278-004-1014-6","volume":"17","author":"A Rosset","year":"2004","unstructured":"Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205\u201316.","journal-title":"J Digit Imaging."},{"key":"2040_CR26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.108.057331","volume":"50","author":"DR Fisher","year":"2009","unstructured":"Fisher DR, Shen S, Meredith RF. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med. 2009;50:644\u201352.","journal-title":"J Nucl Med"},{"key":"2040_CR27","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"2040_CR28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/cbr.2007.302","volume":"22","author":"C Chiesa","year":"2007","unstructured":"Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, et al. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm. 2007;22:113\u201320.","journal-title":"Cancer Biother Radiopharm"},{"key":"2040_CR29","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2967\/jnumed.110.079947","volume":"51","author":"S Baechler","year":"2010","unstructured":"Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010;51:1878\u201384.","journal-title":"J Nucl Med"},{"key":"2040_CR30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Linden O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2040_CR31","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1088\/0031-9155\/54\/19\/014","volume":"54","author":"D Minarik","year":"2009","unstructured":"Minarik D, Ljungberg M, Segars P, Gleisner KS. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging. Phys Med Biol. 2009;54:5873\u201383.","journal-title":"Phys Med Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-2040-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2040-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:05:19Z","timestamp":1558699519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-2040-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2040"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-2040-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}